Publication:
In Vitro Cytogenetic Assessment and Comparison of Vildagliptin and Sitagliptin

dc.authorscopusid57211454819
dc.authorscopusid59788593900
dc.authorscopusid13407057000
dc.authorscopusid37060398600
dc.contributor.authorBörçek Kasurka, C.
dc.contributor.authorElbistan, M.
dc.contributor.authorAtmaca, Ayşegül
dc.contributor.authorAtlı Şekeroğlu, Z.
dc.date.accessioned2020-06-21T12:19:45Z
dc.date.available2020-06-21T12:19:45Z
dc.date.issued2019
dc.departmentOndokuz Mayıs Üniversitesien_US
dc.department-temp[Börçek Kasurka] Ceren, Faculty of Art &Science, Ordu Üniversitesi, Ordu, Turkey; [Elbistan] Mehmet, Department of Medical Biology, Ondokuz Mayis Üniversitesi, Samsun, Turkey; [Atmaca] Ayşegül, Department of Internal Medicine, Ondokuz Mayis Üniversitesi, Samsun, Turkey; [Atlı Şekeroğlu] Zülal, Faculty of Art &Science, Ordu Üniversitesi, Ordu, Turkeyen_US
dc.description.abstractVildagliptin and sitagliptin are commonly used antidiabetic drugs. Chromosomal aberration (CA), sister chromatid exchange (SCE) and cytokinesis-block micronucleus (CBMN) assays were employed to assess and compare cytotoxic and genotoxic effects of these drugs. Peripheral lymphocytes were exposed to 125 μg/ml, 250 μg/ml and 500 μg/ml of vildagliptin and 250 μg/ml, 500 μg/ml and 1000 μg/ml of sitagliptin for 24 h and 48 h with and without exogenous metabolic activation. At the end of the study, it was determined that these drugs and their metabolites had no genotoxic effects on CA, SCE and CBMN. On the other hand, parallel to the increase in dose, vildagliptin showed weak cytotoxicity on the mitotic index, and depending on its increase in dose; sitagliptin caused potential cytotoxicity and cytostatic effect on the mitotic index, nuclear division index and proliferation index. Due to their cytotoxic and cytostatic potential, these drugs inhibit cell proliferation. © 2019, Springer Nature B.V.en_US
dc.identifier.doi10.1007/s10616-019-00345-y
dc.identifier.endpage1077en_US
dc.identifier.issn0920-9069
dc.identifier.issn1573-0778
dc.identifier.issue6en_US
dc.identifier.pmid31555935
dc.identifier.scopus2-s2.0-85074017342
dc.identifier.scopusqualityQ3
dc.identifier.startpage1063en_US
dc.identifier.urihttps://doi.org/10.1007/s10616-019-00345-y
dc.identifier.volume71en_US
dc.identifier.wosWOS:000501172700003
dc.identifier.wosqualityQ4
dc.language.isoenen_US
dc.publisherSpringer editorial@springerplus.comen_US
dc.relation.ispartofCytotechnologyen_US
dc.relation.journalCytotechnologyen_US
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanıen_US
dc.rightsinfo:eu-repo/semantics/openAccessen_US
dc.subjectAntidiabeticen_US
dc.subjectComparisonen_US
dc.subjectIn Vitro Genotoxicityen_US
dc.subjectSitagliptinen_US
dc.subjectVildagliptinen_US
dc.titleIn Vitro Cytogenetic Assessment and Comparison of Vildagliptin and Sitagliptinen_US
dc.typeArticleen_US
dspace.entity.typePublication

Files